Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse
about
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaHigh-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.
P2860
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@en
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@nl
type
label
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@en
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@nl
prefLabel
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@en
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@nl
P2093
P2860
P1433
P1476
Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse
@en
P2093
Andrew Pecora
Anthony Mato
Arun Singavi
Christina Howlett
David Panush
Gabriella Gadaletta
Harry Agress
Kar Fai Chow
Kathryn Waksmundzki
P2860
P304
P356
10.3109/10428194.2013.783909
P577
2013-05-15T00:00:00Z